Nine reports of tumors in children treated with Novartis’ spinal muscular atrophy (SMA) gene therapy Zolgensma raise new questions about its long-term safety. In two cases, viral vector DNA was detected in the patients’ genomes. In 2022, two children had already died of acute liver failure following treatment. The cases illustrate why assessing the safety of gene and cell therapies remains a particular challenge.
ADVERTISEMENT
Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: neuroscience experience for Oculis, an experienced CMO for ARTHEx and manufacturing leadership for CRISPR Therapeutics.
Dutch biotech Anaheim Bio, a spin-out of BioMarin-acquired Alesta Therapeutics, has launched with an oversubscribed €40 million Series A to advance ANA-1, a potential disease-modifying treatment for calcium pyrophosphate deposition disease (CPPD), commonly known as pseudogout, into clinical trials in 2027.
Boehringer is turning to China for cancer research in a multibillion-dollar deal with Sino Biopharmaceutical. Six preclinical programs involving antibody-drug conjugates (ADCs) and T-cell engagers are expected to strengthen its oncology pipeline. Boehringer will initially pay $358 million, with up to another $7 billion tied to development and commercial milestones.
The Mainz-based vaccine developer is making progress in its transformation into an oncology company. But its quarterly report also shows how much work remains: Pumitamig is at the center of clinical development, while other advanced candidates still need to confirm their results. In the meantime, BioNTech is also facing setbacks in its mRNA cancer programs. The collaboration with Bristol Myers Squibb has become a major pillar of revenue — although primarily through contractual payments rather than drug sales.
Bayer brings sevabertinib into the first-line setting in China — but Boehringer is already there: With the approval of sevabertinib for the first-line treatment of HER2-mutated lung cancer, Bayer is expanding access to an important market. The drug is no longer entirely new, nor is it the first in its class in China. Boehringer Ingelheim has already secured a head start with zongertinib.
Cambridge-based T-Therapeutics has raised $133 million (€118 million) in an oversubscribed Series B financing to advance two experimental T-cell engager therapies for cancer and autoimmune diseases into clinical trials. The round brings the University of Cambridge spinout’s total Series A and B funding to $224 million.
University of Oxford spinout Alethio Therapeutics has raised $90 million (about €80 million) to take its G6B-targeting antibody ATX-011 into clinical trials for essential thrombocythemia. The proceeds will fund ATX-011 through Phase 1/2a studies, with the goal of preparing it for Phase 3 development, while advancing additional programs toward applications to begin clinical trials.
French pharmaceutical group Servier has suffered a major setback just four months after completing its $1.55 billion upfront acquisition of Edgewise Therapeutics’ muscular dystrophy business. Sevasemten, the centerpiece of the deal, has failed its pivotal trial in Becker muscular dystrophy, despite encouraging results from earlier studies.
Swedish biotech BioArctic has lost a partnership with Swiss drugmaker Novartis to develop a potential treatment for neurodegenerative diseases using its BrainTransporter technology. The termination eliminates the prospect of up to $772 million (€691 million) in additional payments, although BioArctic retains the $30 million (€27 million) upfront payment.










